Erica Gomez

785 citations

24 papers · 401 indexed · h-index 10

Co-authors: Zi Zhang Wei Li Hui Gan Andrew B. Lassman Lisa Roberts-Rapp Priya Kumthekar Kyle D. Holen Martin J. van den Bent
Topics: Glioma Diagnosis and Treatment (19 papers)Cancer Treatment and Pharmacology (7 papers)Cancer, Hypoxia, and Metabolism (5 papers)
Cited by: Genetics Oncology Cancer Research
Journals: Journal of Clinical Oncology Neurology Clinical Cancer Research
Partner nations: United States Australia Netherlands

In The Last Decade

Erica Gomez

24 papers receiving 397 citations

Peers

Countries citing papers authored by Erica Gomez

Since Specialization

Citations

This map shows the geographic impact of Erica Gomez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erica Gomez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erica Gomez more than expected).

Fields of papers citing papers by Erica Gomez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erica Gomez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erica Gomez. The network helps show where Erica Gomez may publish in the future.

Co-authorship network of co-authors of Erica Gomez

This figure shows the co-authorship network connecting the top 25 collaborators of Erica Gomez. A scholar is included among the top collaborators of Erica Gomez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erica Gomez. Erica Gomez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin 2021 ·Neuro-Oncology Advances ·Hui Gan,Sagun Parakh,Andrew B. Lassman,(unknown),Eddie Lau,Sze Ting Lee,Malaka Ameratunga,(unknown),Diana Cao,Ingrid J.G. Burvenich,Graeme O’Keefe,Angela Rigopoulos,Erica Gomez,David Maag,Andrew M. Scott	9
2	Comparison of Biomarker Assays for EGFR : Implications for Precision Medicine in Patients with Glioblastoma 2019 ·Clinical Cancer Research ·Andrew B. Lassman,Lisa Roberts-Rapp,И. А. Соколова,(unknown),Ekaterina Pestova,(unknown),(unknown),Zheng Zha,Xin Lü,Erica Gomez,Anahita Bhathena,David Maag,Priya Kumthekar,Hui Gan,Andrew M. Scott,(unknown),Kyle D. Holen,Peter Ansell,Martin J. van den Bent	25
3	ACTR-55. TUMOR VOLUME AS A PREDICTOR OF RESPONSE TO ANTI-EGFR ADC ABT-414 2018 ·Neuro-Oncology ·Hui Gan,(unknown),Eddie Lau,Sze-Ting Lee,Malaka Ameratunga,(unknown),Diana Cao,Angela Rigopoulos,Ho‐Jin Lee,Erica Gomez,David Maag,Andrew Scott	2
4	Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized clinical trials in glioblastoma 2017 ·Annals of Oncology ·Martin J. van den Bent,Lisa Roberts-Rapp,Peter Ansell,(unknown),Jim Looman,Earle Bain,Clara B. Ocampo,Kyle D. Holen,Erica Gomez,Andrew B. Lassman	1
5	Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma 2017 ·Neuro-Oncology ·Hui Gan,David A. Reardon,Andrew B. Lassman,Ryan Merrell,Martin J. van den Bent,Nicholas Butowski,Zarnie Lwin,Helen Wheeler,Lisa Fichtel,Andrew M. Scott,Erica Gomez,(unknown),(unknown),Hao Xiong,Ho‐Jin Lee,Wijith Munasinghe,Lisa Roberts-Rapp,Peter Ansell,Kyle D. Holen,Priya Kumthekar	57
6	Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial. 2017 ·Journal of Clinical Oncology ·Andrew B. Lassman,Martin J. van den Bent,Hui Gan,David A. Reardon,Priya Kumthekar,Nicholas Butowski,Zarnie Lwin,Tom Mikkelsen,Burt Nabors,Kyriakos P. Papadopoulos,Marta Peñas-Prado,John Simes,Helen Wheeler,Erica Gomez,Ho‐Jin Lee,Lisa Roberts-Rapp,Hao Xiong,Earle Bain,David Maag,Ryan Merrell	6
7	ACTR-13. EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFICATION RATES OBSERVED IN SCREENING PATIENTS FOR RANDOMIZED CLINICAL TRIALS IN GLIOBLASTOMA 2017 ·Neuro-Oncology ·Martin J. van den Bent,Lisa Roberts-Rapp,Peter Ansell,James Lee,Jim Looman,Earle Bain,Christopher Ocampo,Kyle D. Holen,Erica Gomez,Andrew B. Lassman	1
8	P09.25 Identifying the correct patient (pt) population for ABT414: biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM) 2017 ·Neuro-Oncology ·Andrew B. Lassman,Hui Gan,(unknown),Peter Ansell,Ryan Merrell,Priya Kumthekar,Erica Gomez,Kyle D. Holen,David A. Reardon,Martin J. van den Bent	2
9	PATH-29. MOLECULAR DETERMINANTS ASSOCIATED WITH RESPONSE AND RESISTANCE TO DEPATUXIZUMAB MAFODOTIN (ABT-414) IN PATIENTS WITH RECURRENT GLIOBLASTOMA 2017 ·Neuro-Oncology ·Andrew B. Lassman,Lisa Roberts-Rapp,Lei He,Xin Lü,Martin J. van den Bent,Kyriakos P. Papadopoulos,Ryan Merrell,Priya Kumthekar,David A. Reardon,Erica Gomez,(unknown),Fang Jiang,Zheng Zha,Anahita Bhathena,Kyle D. Holen,Peter Ansell,Hui Gan,Andrew M. Scott	2
10	Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma 2016 ·Neuro-Oncology ·David A. Reardon,Andrew B. Lassman,Martin J. van den Bent,Priya Kumthekar,Ryan Merrell,Andrew M. Scott,Lisa Fichtel,Erik P. Sulman,Erica Gomez,(unknown),Ho‐Jin Lee,Wijith Munasinghe,Hao Xiong,(unknown),Lisa Roberts-Rapp,Peter Ansell,Kyle D. Holen,Hui Gan	86
11	Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM) 2016 ·Annals of Oncology ·Andrew B. Lassman,Martin J. van den Bent,Hui Gan,David A. Reardon,Priya Kumthekar,Nicholas Butowski,Zarnie Lwin,Tom Mikkelsen,Burt Nabors,Kyriakos P. Papadopoulos,Marta Peñas-Prado,John Simes,Helen Wheeler,Erica Gomez,(unknown),Lisa Roberts-Rapp,Hao Xiong,Earle Bain,Kyle D. Holen,Ryan Merrell	2
12	ATNT-01ABT-414 MONO- OR COMBINATION THERAPY WITH TEMOZOLOMIDE (TMZ) RECHALLENGE IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM) AND AMPLIFIED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR): A PHASE I STUDY 2015 ·Neuro-Oncology ·Hui Gan,Priya Kumthekar,Andrew B. Lassman,Ryan Merrell,Martin J. van den Bent,Kyriakos P. Papadopoulos,Andrew M. Scott,Erica Gomez,(unknown),(unknown),Hao Xiong,Ho‐Jin Lee,Wijith Munasinghe,Lisa Roberts-Rapp,Peter Ansell,Kyle D. Holen,Rose Lai,David A. Reardon	2
13	28PD Identifying the correct patient (pt) population for ABT-414: Biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM) 2015 ·Annals of Oncology ·Lisa Roberts-Rapp,Peter Ansell,(unknown),(unknown),И. А. Соколова,Hui Gan,K. Papadopoulos,Andrew B. Lassman,Ryan Merrell,Priya Kumthekar,Andrew M. Scott,Erica Gomez,(unknown),Anahita Bhathena,Kyle D. Holen,Rose Lai,David A. Reardon,Martin J. van den Bent	2
14	2903 Identifying the correct patient (pt) population for ABT-414: Biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM) 2015 ·European Journal of Cancer ·Martin J. van den Bent,Lisa Roberts-Rapp,Peter Ansell,(unknown),Min Song,И. А. Соколова,Hui Gan,K. Papadopoulos,Andrew B. Lassman,Ryan Merrell,Priya Kumthekar,(unknown),Erica Gomez,(unknown),Anahita Bhathena,Kyle D. Holen,Renchun Lai,Dean B. Reardon	2
15	ATNT-02DETERMINANTS OF RESPONSES AND RESISTANCE TO ABT-414: RESULTS OF NEXT-GENERATION SEQUENCING 2015 ·Neuro-Oncology ·Andrew M. Scott,Lisa Roberts-Rapp,Hui Gan,Xin Lü,Andrew B. Lassman,Martin J. van den Bent,Kyriakos P. Papadopoulos,Ryan Merrell,Priya Kumthekar,David A. Reardon,И. А. Соколова,(unknown),(unknown),Erica Gomez,(unknown),Anahita Bhathena,Kyle D. Holen,Rose Lai,Peter Ansell	2
16	Phase I study of ABT-414 mono- or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM). 2015 ·Journal of Clinical Oncology ·Hui Gan,Kyriakos P. Papadopoulos,Lisa Fichtel,Andrew B. Lassman,Ryan Merrell,Martin J. van den Bent,Priya Kumthekar,Andrew M. Scott,(unknown),Erica Gomez,(unknown),(unknown),Hao Xiong,(unknown),Wijith Munasinghe,Lisa Roberts-Rapp,Peter Ansell,Kyle D. Holen,Rose Lai,David A. Reardon	17
17	ET-19 * A PHASE 1 STUDY EVALUATING ABT-414 WITH TEMOZOLOMIDE (TMZ) OR CONCURRENT RADIOTHERAPY (RT) AND TMZ IN GLIOBLASTOMA (GBM) 2014 ·Neuro-Oncology ·Hui Gan,Lisa Fichtel,Andrew B. Lassman,Ryan Merrell,Martin J. van den Bent,Priya Kumthekar,Andrew M. Scott,(unknown),Erica Gomez,(unknown),(unknown),Hao Xiong,(unknown),Wijith Munasinghe,Lisa Roberts-Rapp,Peter Ansell,Kyle D. Holen,David A. Reardon	6
18	A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM). 2014 ·Journal of Clinical Oncology ·Hui Gan,Lisa Fichtel,Andrew B. Lassman,Ryan Merrell,Martin J. van den Bent,Priya Kumthekar,Andrew M. Scott,(unknown),Erica Gomez,(unknown),(unknown),Hao Xiong,Matthew W. Dudley,Wijith Munasinghe,Lisa Roberts-Rapp,Peter Ansell,Kyle D. Holen,David A. Reardon	16
19	Pharmacological characterization of A-960656, a histamine H3 receptor antagonist with efficacy in animal models of osteoarthritis and neuropathic pain 2012 ·European Journal of Pharmacology ·Marlon Cowart,Gin C. Hsieh,Lawrence A. Black,Cenchen Zhan,Erica Gomez,Madhavi Pai,Marina I. Strakhova,Arlene M. Manelli,Tracy L. Carr,Jill M. Wetter,Anthony Lee,Gilbert Diaz,Tiffany Runyan Garrison,Jorge D. Brioni	22
20	Characterization of nerve growth factor‐induced mechanical and thermal hypersensitivity in rats 2012 ·European Journal of Pain ·Charles D. Mills,Timothy Nguyen,Flobert Tanga,Chengmin Zhong,Donna M. Gauvin,Joseph P. Mikusa,Erica Gomez,Anita K. Salyers,Anthony W. Bannon	55

About Erica Gomez

Erica Gomez is a scholar working on Genetics, Oncology and Cancer Research, having authored 24 papers that have together received 401 indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (19 papers), Cancer Treatment and Pharmacology (7 papers) and Cancer, Hypoxia, and Metabolism (5 papers). The work is most often cited by research in Genetics (159 citations), Oncology (157 citations) and Cancer Research (64 citations). Erica Gomez has collaborated with scholars based in United States, Australia and Netherlands. Frequent co-authors include Zi Zhang, Wei Li, Hui Gan, Andrew B. Lassman, Lisa Roberts-Rapp, Priya Kumthekar, Kyle D. Holen, Martin J. van den Bent, Andrew M. Scott and Peter Ansell. Their work appears in journals such as Journal of Clinical Oncology, Neurology and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact